[Demonstration of secondary free radicals and the role of calpain in functional changes associated with the myocardial ischemia-reperfusion sequence].
The aim of this study was to investigate the role of secondary free radicals and calpain, a calcium-activated cysteine protease, in the development of reperfusion injury in the heart. The time course of radical generation was assessed directly by Electron Paramagnetic Resonance (EPR) and spin trapping with N-ter butyl-alpha-phenylnitrone (PBN), in isolated perfused rat heart subjected to 30 minutes of global ischemia and 30 minutes of reperfusion. The effect of leupeptin, a calpain inhibitor, was assessed on postischemic dysfunction. The antioxidant properties of leupeptin were also investigated by using allophycocyanin, a fluorescent protein sensitive to oxidative stress generated by the H2O2 + Cu++ system. Moreover, we measured the capacities of leupeptin to scavenge hydroxyl (.OH) and superoxide (O2-.) radicals using EPR technique. Our results show that myocardial reperfusion is associated with an increase of alkyl, alkoxyl free radicals release; the administration of catalase 5.10(5) UI/L significantly reduces this release, but didn't improve the postischemic contractile function of the heart. In our study leupeptin 50 microM possess, in vitro, antioxidant properties and scavenging abilities against .OH and O2-., in return leupeptin does not influence the cardiac functions during reperfusion period. In conclusion, our results confirm that myocardial reperfusion induces an important production of secondary free radicals associated with contractile dysfunction. The role of calpain in myocardial ischemia-reperfusion injury remains to be clarified 1) by assessing the activities of calpain and calpastain, its main endogenous inhibitor, during these periods, 2) by measuring the ability of leupeptin in inhibiting the calpain dependent proteolysis.
Perrin
C
C
Vergely
C
C
Zeller
M
M
Maupoil
V
V
Rochette
L
L
D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000494:pharmacology; D002154:Calpain / Q000037:antagonists & inhibitors / Q000502:physiology*; D002374:Catalase / Q000494:pharmacology; D002403:Cathepsins / Q000037:antagonists & inhibitors; D003497:Cyclic N-Oxides; D015853:Cysteine Proteinase Inhibitors / Q000378:metabolism / Q000494:pharmacology; D004578:Electron Spin Resonance Spectroscopy; D016166:Free Radical Scavengers / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism*; D017665:Hydroxyl Radical / Q000378:metabolism; D007976:Leupeptins / Q000378:metabolism / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000201:enzymology / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D009589:Nitrogen Oxides; D018384:Oxidative Stress / Q000502:physiology; D010798:Phycocyanin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013113:Spin Labels; D013481:Superoxides / Q000378:metabolism; D013997:Time Factors
D000975:Antioxidants; D002135:Calcium-Binding Proteins; D003497:Cyclic N-Oxides; D015853:Cysteine Proteinase Inhibitors; D016166:Free Radical Scavengers; D005609:Free Radicals; D007976:Leupeptins; D009589:Nitrogen Oxides; D013113:Spin Labels; C002497:allophycocyanin; D010798:Phycocyanin; D013481:Superoxides; D017665:Hydroxyl Radical; C029217:phenyl-N-tert-butylnitrone; C033668:calpastatin; D002374:Catalase; D002403:Cathepsins; D002154:Calpain; C032854:leupeptin